Eniluracil

Drug Profile

Eniluracil

Alternative Names: 5-Ethynyluracil; 5-EU; 776C85; ADH 300004; GW 776C85

Latest Information Update: 17 Aug 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Adherex Technologies; Fennec Pharmaceuticals; GlaxoSmithKline
  • Class Antineoplastics; Chemosensitisers; Pyrimidinones; Small molecules
  • Mechanism of Action Dihydropyrimidine dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Breast cancer
  • Discontinued Colorectal cancer; Erythrodysaesthesia; Head and neck cancer; Hepatocellular carcinoma; Pancreatic cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 03 Sep 2014 Adherex is now called Fennec Pharmaceuticals
  • 09 Aug 2013 Eniluracil is available for licensing as of 09 Aug 2013. www.adherex.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top